Colombo Daniele, Gatti Arianna, Alabardi Patrizia, Bompane Daniela, Bonardi Giorgio, Mumoli Nicola, Faggioli Paola, Clerici Pierangelo, Brando Bruno, Mazzone Antonino
Internal Medicine Unit, Legnano Hospital, ASST Ovest Milanese, Legnano (MI), Italy.
Hematology Laboratory and Transfusion Center, Legnano Hospital, ASST Ovest Milanese, Legnano (MI), Italy.
J Hematol. 2022 Apr;11(2):77-80. doi: 10.14740/jh845. Epub 2022 Apr 22.
Coronavirus disease 2019 (COVID-19) can have a severe course in immunocompromised hosts and patients with hematological malignancies. In some cases, the bad prognosis is associated with the lack of B lymphocytes, with impaired antibody production and inefficient viral clearance. We report a case of a 67-year-old woman with a story of non-Hodgkin lymphoma treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), who got a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection while being totally depleted of B cells. This condition has determined a severe and prolonged course of COVID-19, with persistently positive nasopharyngeal molecular swabs and lack of anti-SARS-CoV-2 specific antibodies. The clinical recovery was favored by the administration of convalescent hyperimmune plasma.
2019冠状病毒病（COVID-19）在免疫功能低下的宿主和血液系统恶性肿瘤患者中可能会有严重的病程。在某些情况下，不良预后与B淋巴细胞缺乏、抗体产生受损和病毒清除效率低下有关。我们报告一例67岁女性，有非霍奇金淋巴瘤病史，接受R-CHOP（利妥昔单抗加环磷酰胺、多柔比星、长春新碱和泼尼松）治疗，在B细胞完全耗竭时感染了严重急性呼吸综合征冠状病毒2（SARS-CoV-2）。这种情况导致了COVID-19的严重和延长病程，鼻咽分子拭子持续呈阳性，且缺乏抗SARS-CoV-2特异性抗体。恢复期高免疫血浆的输注有利于临床康复。
